8-K/A: Calidi Biotherapeutics Files Amendment to Form 8-K to Include Auditor Consent
Form 8-K/A Amendment
Calidi Biotherapeutics amends its previous Form 8-K filing to include the consent of its independent registered public accounting firm, Marcum LLP.
Summary
- Calidi Biotherapeutics, Inc. filed an amendment (Amendment No. 1) to its Current Report on Form 8-K/A, initially filed on January 10, 2025.
- The purpose of the amendment is to add Exhibit 23.1, which is the consent of Marcum LLP, the company's independent registered public accounting firm.
- The consent relates to their audit report dated March 15, 2024, regarding the consolidated financial statements for the years ended December 31, 2023 and 2022.
- The audit report includes an explanatory paragraph concerning the company's ability to continue as a going concern.
- The consent also references the reverse stock split described in Note 1, with the date related to the effects of the split being December 11, 2024.
- The consent is in connection with the Registration Statement on Form S-1 (File No. 333-283741).
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
The filing of auditor consent is a standard regulatory requirement for companies listed on exchanges like NYSE American LLC, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The filing ensures compliance with regulatory requirements, which is important for maintaining investor confidence.
Key Dates
| Date | Description |
|---|---|
| March 15, 2024 | Date of Marcum LLP's audit report (except for the effects of the reverse stock split). |
| December 11, 2024 | Date related to the effects of the reverse stock split described in Note 1. |
| January 10, 2025 | Date of the Initial Form 8-K filing. |
| February 10, 2025 | Date of the amended Form 8-K/A filing and the date of Marcum LLP's consent. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.